5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy

M. Cusini, F. Salmaso, R. Zerboni, G. Carminati, C. Vernaci, C. Franchi, A. Locatelli, E. Alessi

Research output: Contribution to journalArticlepeer-review

Abstract

The efficacy of imiquimod in the treatment of external genital warts in HIV positive subjects was compared to a group of patients with normal immune function. Imiquimod 5% cream was applied by patients three times a week until resolution for a maximum of 16 weeks. Assessment for response and the occurrence of side effects was performed every four weeks. Thirty-one per cent of 75 HIV positive patients achieved a complete clearance, a partial response was obtained in 24% of subjects while in 45% we observed no clinical response. In the control group a total clearance was obtained in 62% of subjects, a partial response in 24% and no response in 14%. Recurrences occurred in 4/23 HIV patients and 2/31 immunocompetent patients within three months of follow-up. Side effects were minor to moderate. We conclude that imiquimod 5% cream has an acceptable efficacy and safety on HIV patients.

Original languageEnglish
Pages (from-to)17-20
Number of pages4
JournalInternational Journal of STD and AIDS
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2004

Keywords

  • External genital warts
  • HIV-infection
  • Imiquimod

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Immunology

Fingerprint

Dive into the research topics of '5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy'. Together they form a unique fingerprint.

Cite this